84 related articles for article (PubMed ID: 19521045)
1. [Indicators for insulin therapy in late elderly patients with type 2 diabetes mellitus--the relationship between plasma C-peptide on glucagon load test and insulin therapy].
Miyamoto M
Nihon Ronen Igakkai Zasshi; 2009 May; 46(3):244-9. PubMed ID: 19521045
[TBL] [Abstract][Full Text] [Related]
2. Postprandial serum C-peptide value is the optimal index to identify patients with non-obese type 2 diabetes who require multiple daily insulin injection: Analysis of C-peptide values before and after short-term intensive insulin therapy.
Fujiwara D; Takahashi K; Suzuki T; Shii M; Nakashima Y; Takekawa S; Yoshida A; Matsuoka T
J Diabetes Investig; 2013 Nov; 4(6):618-25. PubMed ID: 24843717
[TBL] [Abstract][Full Text] [Related]
3. C-peptide response to glucagon in type 2 diabetes mellitus: a comparison with oral glucose tolerance test.
Iwasaki Y; Kondo K; Hasegawa H; Oiso Y
Diabetes Res; 1994; 25(3):129-37. PubMed ID: 7671552
[TBL] [Abstract][Full Text] [Related]
4. Secondary failure to oral hypoglycaemic agents in non-obese patients with non-insulin-dependent diabetes is related to reduced insulin release.
Pontiroli AE; Calderara A; Maffi P; Bonisolli L; Carenini A; Piatti PM; Monti LD; Gallus G; Pozza G; Illeni MT
Diabete Metab; 1989; 15(2):79-84. PubMed ID: 2661281
[TBL] [Abstract][Full Text] [Related]
5. Increment of serum C-peptide measured by glucagon test closely correlates with human relative beta-cell area.
Fujita Y; Kozawa J; Iwahashi H; Yoneda S; Uno S; Yoshikawa A; Okita K; Eguchi H; Nagano H; Imagawa A; Shimomura I
Endocr J; 2015; 62(4):329-37. PubMed ID: 25740613
[TBL] [Abstract][Full Text] [Related]
6. A reliable serum C-peptide index for the selection of an insulin regimen to achieve good glycemic control in obese patients with type 2 diabetes: an analysis from a short-term study with intensive insulin therapy.
Suzuki T; Takahashi K; Fujiwara D; Shii M; Takekawa S; Matsuoka T
Diabetol Int; 2016 Sep; 7(3):235-243. PubMed ID: 30603269
[TBL] [Abstract][Full Text] [Related]
7. Clinical Utility of the Meal Tolerance Test in the Care of Patients with Type 2 Diabetes Mellitus.
Wakasaki H; Shono T; Nakao R; Yamamoto S; Minaga T; Fukuda S; Matsumoto R; Ohoshi T; Naka K; Nanjo K
Intern Med; 2020; 59(18):2229-2235. PubMed ID: 32938850
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic B-cell function in non-insulin-dependent diabetes mellitus during successive periods of sulfonylurea and insulin treatment: serum C-peptide response to glucagon and urine C-peptide excretion.
Hsieh SD; Iwamoto Y; Matsuda A; Kuzuya T
Endocrinol Jpn; 1987 Aug; 34(4):561-7. PubMed ID: 3315640
[TBL] [Abstract][Full Text] [Related]
9. Utility of indices using C-peptide levels for indication of insulin therapy to achieve good glycemic control in Japanese patients with type 2 diabetes.
Funakoshi S; Fujimoto S; Hamasaki A; Fujiwara H; Fujita Y; Ikeda K; Takahara S; Nagashima K; Hosokawa M; Seino Y; Inagaki N
J Diabetes Investig; 2011 Aug; 2(4):297-303. PubMed ID: 24843502
[TBL] [Abstract][Full Text] [Related]
10. A study of serum free C-peptide responses to oral glucose load in diabetic patients: with special reference to types of diabetes and methods of treatment.
Hsieh SD; Akanuma Y; Takaku F
Tohoku J Exp Med; 1984 Mar; 142(3):249-60. PubMed ID: 6374968
[TBL] [Abstract][Full Text] [Related]
11. [Pancreatic B cell function and glucose intolerance in the elderly].
Nozaki T
Nihon Ika Daigaku Zasshi; 1989 Apr; 56(2):153-65. PubMed ID: 2659622
[TBL] [Abstract][Full Text] [Related]
12. Serum free C-peptide response to oral glucose loading as a parameter for the monitoring of pancreatic B-cell function in diabetic patients.
Hsieh SD; Kanazawa Y; Akanuma Y
Diabetes Res Clin Pract; 1985 Aug; 1(2):109-14. PubMed ID: 3915258
[TBL] [Abstract][Full Text] [Related]
13. Increment of C-peptide after glucagon injection determines the progressive nature of Japanese type 2 diabetes: a long-term follow-up study.
Fukui T; Oono K; Hara N; Yamamoto T; Nagashima M; Naito H; Hirano T
Endocr J; 2013; 60(6):715-24. PubMed ID: 23386398
[TBL] [Abstract][Full Text] [Related]
14. Postprandial serum C-peptide to plasma glucose ratio as a predictor of subsequent insulin treatment in patients with type 2 diabetes.
Saisho Y; Kou K; Tanaka K; Abe T; Kurosawa H; Shimada A; Meguro S; Kawai T; Itoh H
Endocr J; 2011; 58(4):315-22. PubMed ID: 21415555
[TBL] [Abstract][Full Text] [Related]
15. Analysis of insulin secretion based on changes in plasma insulin and C-peptide in man.
Sakai T; Ohneda A; Nihei J; Kobayashi T
Tohoku J Exp Med; 1982 Dec; 138(4):427-40. PubMed ID: 6761899
[TBL] [Abstract][Full Text] [Related]
16. Correlation of serum CPR to plasma glucose ratio with various indices of insulin secretion and diseases duration in type 2 diabetes.
Okuno Y; Sakaguchi K; Komada H; Hashimoto N; Hirota Y; Nakamura T; Ogawa W; Seino S
Kobe J Med Sci; 2013 Apr; 59(2):E44-53. PubMed ID: 23756662
[TBL] [Abstract][Full Text] [Related]
17. Postprandial serum C-peptide to plasma glucose concentration ratio correlates with oral glucose tolerance test- and glucose clamp-based disposition indexes.
Okuno Y; Komada H; Sakaguchi K; Nakamura T; Hashimoto N; Hirota Y; Ogawa W; Seino S
Metabolism; 2013 Oct; 62(10):1470-6. PubMed ID: 23831440
[TBL] [Abstract][Full Text] [Related]
18. Influence of exogenous insulin on C-peptide levels in subjects with type 2 diabetes.
Albareda M; Rigla M; Rodríguez-Espinosa J; Caballero A; Chico A; Cabezas R; Carreras G; Pérez A
Diabetes Res Clin Pract; 2005 Jun; 68(3):202-6. PubMed ID: 15936461
[TBL] [Abstract][Full Text] [Related]
19. Preoperative insulin secretion ability and pancreatic parenchymal thickness as useful parameters for predicting postoperative insulin secretion in patients undergoing pancreaticoduodenectomy.
Yoshikawa A; Kozawa J; Okita K; Yoneda S; Okauchi Y; Uno S; Iwahashi H; Ohira T; Takiuchi D; Eguchi H; Takeda Y; Imagawa A; Shimomura I
Endocr J; 2012; 59(5):383-92. PubMed ID: 22374239
[TBL] [Abstract][Full Text] [Related]
20. Glucagon Test Is a Useful Predictor of Withdrawal From Insulin Therapy in Subjects With Type 2 Diabetes Mellitus.
Iwamoto Y; Kimura T; Tatsumi F; Sugisaki T; Kubo M; Nakao E; Dan K; Wamata R; Iwamoto H; Takahashi K; Sanada J; Fushimi Y; Katakura Y; Shimoda M; Nakanishi S; Mune T; Kaku K; Kaneto H
Front Endocrinol (Lausanne); 2022; 13():871660. PubMed ID: 35574023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
